Zahájení studie Sample Clauses

Zahájení studie. (a) The Provider of health services shall not, shall not permit the Physician to, commence recruitment of potential Study Subjects to participate in the Study unless and until the Physician (i) is notified by Biogen Idec or its agents in writing that all approvals, authorizations and documentation necessary to conduct the Study have been obtained; and (ii) has signed the Protocol and thereby agreed to conduct the Study in accordance with the terms and the conditions of the Protocol. (a) Poskytovatel zdravotních služeb nezahájí a nedovolí lékaři zahájit nábor potenciálních subjektů hodnocení pro účast ve studii, dokud lékař (i) nebude společností Biogen Idec nebo jejími zástupci písemně informován, že byly získány všechny souhlasy, povolení a dokumentace potřebná k provádění studie; a (ii) nepodepsal protokol a nepřistoupil tak na provádění studie v souladu s podmínkami protokolu.
Sample 1
AutoNDA by SimpleDocs
Zahájení studie. (a) Zdravotnické zařízení a lékař nezahájí nábor potenciálních subjektů studie pro účast ve studii, dokud zdravotnické zařízení a lékař (i) nebudou společností Biogen nebo jejími zástupci písemně informováni, že byly získány všechny souhlasy, povolení a dokumentace potřebné k provádění studie; a dokud lékař (ii) nepodepíše protokol a neodsouhlasí, že bude studii provádět v souladu s podmínkami protokolu. Zdravotnické zařízení a lékař dále nebudou provádět výzkum podle této smlouvy, pokud a dokud subjekt studie písemně nepotvrdí převzetí, prostudování a podepsání formuláře informovaného souhlasu pro studii s tím, že formulář informovaného souhlasu byl předem schválen společností Biogen a poskytnut lékaři. (b) The Institution shall appoint the Physician and any personnel (the “Staff”), necessary to support the conduct of the Study. The Institution shall ensure that the Physician and the Staff have the relevant qualifications to perform their obligations under this Agreement and that they shall at all times comply with the terms and obligations of this Agreement. The Institution represents and warrants that Institution has, or will obtain, from all Staff, including the Physician, agreements that impose on such Staff (i) confidentiality obligations at least as restrictive as those applicable to Institution hereunder and (ii) assignment of invention obligations that effectively vest in the Institution and Physician any rights the Staff may otherwise have in the results of their work in connection with the Study and permit the Institution and Physician to assign those rights to Biogen . The Institution and Physician shall provide Biogen or its authorized agents with information regarding the Staff as necessary to comply with applicable laws, regulations and directives, or as Biogen or its authorized agents may reasonably request. For the avoidance of doubt, the Staff shall, throughout the term of this Agreement, be under the supervision and control of the Institution and Physician and the Institution and Physician shall, without limitation, be responsible for ensuring that the Staff act in accordance with the Applicable Laws and Regulations (as defined below), the terms of this Agreement and Biogen ’s or its agents’ reasonable instructions. (b) Zdravotnické zařízení určí lékaře a pracovníky potřebné k zajištění provádění studie (dále jen „tým“). Zdravotnické zařízení zajistí, aby lékař a tým měli k plnění svých povinností dle této smlouvy odpovídající kvalifikac...
Sample 1
Zahájení studie. (a) The Institution shall not, and shall not permit the Physician to, commence recruitment of potential Study Subjects to participate in the Study unless and until the Physician (i) is notified by Biogen Idec or its agents in writing that all approvals, authorizations and documentation necessary to conduct the Study have been obtained; and (ii) has signed the Protocol and thereby agreed to conduct the Study in accordance with the terms and the conditions of the Protocol. Further, the Physician shall not conduct research covered under this Agreement unless and until the Study Subject has confirmed, in writing, receipt and review and execution of, an informed consent form for the Study, which form shall have been previously approved by Biogen Idec and provided to the Physician. (a) Zdravotnické zařízení nezahájí ani nedovolí lékaři zahájit xxxxx potenciálních subjektů hodnocení pro účast ve studii, dokud lékař (i) nebude společností Biogen Idec nebo jejími zástupci písemně informován, že byly získány všechny souhlasy, povolení a dokumentace potřebná k provádění studie; a (ii) nepodepsal protokol a nepřistoupil tak na provádění studie v souladu s podmínkami protokolu. Xxxxx xxxx nebude provádět výzkum podle této smlouvy, pokud a dokud subjekt hodnocení písemně nepotvrdí převzetí, prostudování a podepsání formuláře informovaného souhlasu pro studii s xxx, že formulář informovaného souhlasu byl předem schválen společností Biogen Idec a poskytnut lékaři. (b) The Institution shall appoint the Physician and the personnel (the “Staff”), necessary to support the conduct of the Study. The Physician declares that he has the relevant qualifications to perform his obligations under this Agreement and that he shall at all times comply with the terms and obligations of this Agreement. The Physician shall ensure that Staff have the relevant qualifications to perform their obligations under this Agreement and that they shall at all times comply with the terms and obligations of this Agreement. The Physician represents and warrants that he has or will obtain from all Staff, himself, agreements that impose on such Staff confidentiality obligations at least as restrictive as those applicable to Institution or Physician, and the Institution represents and warrants that the Institution has or will obtain from all Staff, including the Physician, agreements that impose on such Staff assignment of invention obligations that effectively vest in the Institution any rights the Staff m...
Sample 1
Zahájení studie. Léčba Subjektů Studie nebude zahájena, dokud nebudou obdržena veškerá schválení etických komisí, souhlas SÚKL a jakákoliv xxxx svolení potřebná k zahájení Studie. 1.4 Zdravotní záznamy a Studijní data a údaje 1.4.1
Sample 1
Zahájení studie. (a) The Institution shall not, and shall not permit the Physician to, commence recruitment of potential Study Subjects to participate in the Study unless and until the Physician (i) is notified by Biogen Idec or its agents in writing that all approvals, authorizations and documentation necessary to conduct the Study have been obtained; and (ii) has signed the Protocol and thereby agreed to conduct the Study in accordance with the terms and the conditions of the Protocol. Further, the Physician shall not conduct research covered under this Agreement unless and until the Study Subject has confirmed, in writing, receipt and review and execution of, an informed consent form for the Study, which form shall have been previously approved by Biogen Idec and provided to the Physician. (a) Zdravotnické zařízení nezahájí ani nedovolí lékaři zahájit xxxxx potenciálních subjektů hodnocení pro účast ve studii, dokud lékař (i) nebude společností Biogen Idec nebo jejími zástupci písemně informován, že byly získány všechny souhlasy, povolení a dokumentace potřebná k provádění studie; a (ii) nepodepsal protokol a nepřistoupil tak na provádění studie v souladu s podmínkami protokolu. Xxxxx xxxx nebude provádět výzkum podle této smlouvy, pokud a dokud subjekt hodnocení písemně nepotvrdí převzetí, prostudování a podepsání formuláře informovaného souhlasu pro studii s xxx, že formulář informovaného souhlasu byl předem schválen společností Biogen Idec a poskytnut lékaři.
Sample 1

Related to Zahájení studie

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 1.1. Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • The Study 2.1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

Time is Money Join Law Insider Premium to draft better contracts faster.